Mer­ck, Pfiz­er tout PhI­II di­a­betes da­ta as er­tugli­fozin heads to the FDA

Mer­ck and Pfiz­er rolled out pos­i­tive Phase III da­ta for their SGLT2 di­a­betes drug er­tugliflozin at the an­nu­al EASD meet­ing in Ger­many to­day.

The da­ta, with two dos­es of their drug added to Janu­via and met­formin slic­ing A1c lev­els by an ex­tra 0.69 per­cent and 0.76 per­cent, will be added to their reg­u­la­to­ry fil­ings for this drug, now slat­ed to land at the FDA be­fore the end of this year with Eu­rope and oth­er mar­kets to fol­low in 2017.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.